Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Mulvihill, Erin E
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. [electronic resource] - Peptides 02 2018 - 158-164 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1873-5169
10.1016/j.peptides.2017.11.023 doi
Blood Glucose--drug effects
Diabetes Mellitus, Type 2--drug therapy
Dipeptidyl Peptidase 4--genetics
Dipeptidyl-Peptidase IV Inhibitors--therapeutic use
Glucose--metabolism
Humans
Incretins--metabolism
Lipid Metabolism--drug effects
Postprandial Period
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. [electronic resource] - Peptides 02 2018 - 158-164 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1873-5169
10.1016/j.peptides.2017.11.023 doi
Blood Glucose--drug effects
Diabetes Mellitus, Type 2--drug therapy
Dipeptidyl Peptidase 4--genetics
Dipeptidyl-Peptidase IV Inhibitors--therapeutic use
Glucose--metabolism
Humans
Incretins--metabolism
Lipid Metabolism--drug effects
Postprandial Period